BACKGROUND: Gastroesophageal reflux disease (GERD) is a common condition, and acid-suppressing agents are the mainstays of treatment. For the acute medical management of GERD, two different strategies can be proposed: either the most effective therapy, i.e., proton-pump inhibitors (PPIs), can be given first, or histamine H2-receptor antagonists (H2RAs) can be attempted first (the "step-up" approach). METHODS: A clinical decision analysis comparing the PPI-first strategy and the H2RA-first "step-up" strategy for the acute treatment of reflux esophagitis in Japan was performed, using a Markov chain approach. RESULTS: The PPI-first strategy was consistently superior to the step-up strategy with regard to clinical outcomes for the patient and with regard to cost-effectiveness (direct cost per patient to achieve clinical success). This superiority was robust within the plausible range of probabilities according to the sensitivity analyses. CONCLUSIONS: The PPI-first strategy is superior to the H2RA-first "step-up" strategy with regard to both efficacy and cost-effectiveness and therefore, the PPI-first strategy is the preferred therapeutic approach for the acute medical treatment of reflux esophagitis.
BACKGROUND: Gastroesophageal reflux disease (GERD) is a common condition, and acid-suppressing agents are the mainstays of treatment. For the acute medical management of GERD, two different strategies can be proposed: either the most effective therapy, i.e., proton-pump inhibitors (PPIs), can be given first, or histamine H2-receptor antagonists (H2RAs) can be attempted first (the "step-up" approach). METHODS: A clinical decision analysis comparing the PPI-first strategy and the H2RA-first "step-up" strategy for the acute treatment of reflux esophagitis in Japan was performed, using a Markov chain approach. RESULTS: The PPI-first strategy was consistently superior to the step-up strategy with regard to clinical outcomes for the patient and with regard to cost-effectiveness (direct cost per patient to achieve clinical success). This superiority was robust within the plausible range of probabilities according to the sensitivity analyses. CONCLUSIONS: The PPI-first strategy is superior to the H2RA-first "step-up" strategy with regard to both efficacy and cost-effectiveness and therefore, the PPI-first strategy is the preferred therapeutic approach for the acute medical treatment of reflux esophagitis.
Authors: N Furukawa; R Iwakiri; T Koyama; K Okamoto; T Yoshida; Y Kashiwagi; T Ohyama; T Noda; H Sakata; K Fujimoto Journal: J Gastroenterol Date: 1999-08 Impact factor: 7.527
Authors: S J Sontag; D G Kogut; R Fleischmann; D R Campbell; J Richter; M Robinson; M McFarland; S Sabesin; G A Lehman; D Castell Journal: Am J Gastroenterol Date: 1997-03 Impact factor: 10.864
Authors: M Feldman; W V Harford; R S Fisher; R E Sampliner; S B Murray; P A Greski-Rose; D E Jennings Journal: Am J Gastroenterol Date: 1993-08 Impact factor: 10.864
Authors: K D Bardhan; C J Hawkey; R G Long; A G Morgan; K G Wormsley; I K Moules; D Brocklebank Journal: Aliment Pharmacol Ther Date: 1995-04 Impact factor: 8.171
Authors: C M Bate; S N Booth; J P Crowe; R A Mountford; P W Keeling; B Hepworth-Jones; M D Taylor; P D Richardson Journal: Gut Date: 1995-04 Impact factor: 23.059
Authors: Serhat Bor; İsmail Hakkı Kalkan; Altay Çelebi; Dinç Dinçer; Filiz Akyüz; Peter Dettmar; Hasan Özen Journal: Turk J Gastroenterol Date: 2019-09 Impact factor: 1.852
Authors: Stacy B Menees; Amanda Guentner; Samuel W Chey; Richard Saad; William D Chey Journal: Am J Gastroenterol Date: 2015-06-09 Impact factor: 10.864